SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating Middle East tensions and significant disruptions to the Strait of Hormuz drive oil prices to multi-year highs with historic weekly gains. Traders are fiercely debating whether this represents a sustainable "plumbing break" or an overextended "fear trade" ripe for a pullback, amidst discussions of potential US administration interventions to stabilize the market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Community excitement for Capricor Therapeutics is surging, driven by news of a key FDA official's departure, with many believing this removes a significant hurdle for Deramiocel's approval for Duchenne Muscular Dystrophy and could trigger a substantial short squeeze ahead of upcoming Phase 3 data presentation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending as the community speculates that the impending departure of a key FDA official could lead to a more favorable regulatory path for its Huntington's disease gene therapy, AMT-130, after prior setbacks. This has sparked intense debate between those anticipating accelerated approval for gene therapies and bears who remain skeptical of the underlying drug data and the sustainability of the rally.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending following news of an AI licensing partnership in Africa, sparking intense community discussion and predictions of a significant short squeeze driven by its notably low float and high cost to borrow.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility, drawing polarized community sentiment between dip-buyers confident in long-term AI demand and short-sellers citing geopolitical concerns and the ETF's repeated failure to break key resistance. The leveraged semiconductor fund is seeing rapid swings, driven by mixed reactions to sector earnings and broader market uncertainty.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences (SLS) is gaining significant attention after its CEO highlighted potential "curative outcomes" for AML with GPS and SLS009, reinforcing expectations of extended patient survival in the REGAL trial and fueling widespread community speculation of an impending buyout and substantial short squeeze.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as its community intensely debates the crypto's future, with many users expressing frustration over stalled KYC processes, unverified balances, and the lack of major exchange listings, while others remain steadfast in their long-term bullish outlook for the project.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is drawing significant attention following its S&P 500 inclusion, which is expected to drive institutional buying, and a substantial $2 billion investment from NVIDIA to secure advanced optical technology for AI data centers. While many are bullish on LITE's pivotal role in AI infrastructure, a segment of the community debates its rapid, "parabolic" valuation and the potential for a sharp correction.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending with surging volume, fueled by intense short-covering and bullish community sentiment. Investors are optimistic about a significant re-rating, citing recent analyst upgrades, M&A buzz in the oncology sector, and anticipated data readouts for its promising TIL therapy platform.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

Heightened geopolitical tensions surrounding Iran, rising oil prices, and a recent weaker jobs report are driving IWM's trend, as the community actively debates whether these catalysts signal a significant downturn for small-cap stocks or a strategic buying opportunity. Traders are closely monitoring IWM's key price levels, recognizing its role as a highly volatile bellwether for overall market sentiment amid global uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners investor summit.</li><li>Cadrenal said VLX-1005 has completed a Phase 2 trial, with data under review and FDA discussions planned.</li><li>Shares fell 4% on Friday before ticking higher after the close.</li></ul>Cadrenal Therapeutics drew renewed retail investor interest on Tuesday after&nbsp;the biotech company&nbsp;outlined progress across its anticoagulation pipeline, VLX-1005,&nbsp; which it&nbsp;acquired from Veralox Therapeutics in December.At a&nbsp;fireside chat at the Lytham Partners Healthcare Investor Summit,&nbsp;Cadrenal CEO Quang Pham and acting Chief Scientific Officer Matt Boxer described how the asset fits into the company’s broader strategy to address gaps left by long-standing anticoagulants such as Warfarin and Heparin, as well as newer direct oral anticoagulants (DOACs).The stock fell 4% to close at $7.87 on Friday, before edging up 0.8% in after-hours trading.<h2 class="st-heading-2">Targeting A High-Risk Complication Of Heparin Use</h2>VLX-1005 is being developed for heparin-induced thrombocytopenia, or HIT, a condition caused by an immune reaction to heparin. Boxer said patients exposed to heparin can develop antibodies that form complexes with platelet factor 4.This process leads to platelet consumption while simultaneously triggering clot formation, he said. As a result, patients can develop thrombosis and ischemia, with cases sometimes progressing to amputations, organ failure, and death, even though they were initially given heparin for anticoagulation.Boxer said existing treatments mainly work by inhibiting the clotting cascade, a strategy that can increase bleeding risk in patients with already low platelet counts. He added that about 50,000 confirmed new HIT cases occur each year in the U.S., driven in part by the continued use of heparin in cardiovascular surgery, with cases also seen globally.<h2 class="st-heading-2">Phase 2 Data And Next Steps</h2>VLX-1005 was designed to act earlier in the disease process by blocking 12-lipoxygenase (12-LOX), an enzyme that plays a role in triggering immune-driven platelet activation.&nbsp;The program has completed a Phase 2 clinical trial, with the database locked and data currently under analysis. Pham said the company has been engaging with primary investigators through introductions made by the Veralox team and expects the data to be published in the near term.VLX-1005 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). Pham said work on chemistry, manufacturing and controls is underway, with discussions with the FDA expected later this quarter.<h2 class="st-heading-2">Other Programs In Development</h2>Alongside VLX-1005, Cadrenal is advancing Tecarfarin, a vitamin K antagonist designed to be more kidney-friendly, for patients with end-stage kidney disease and atrial fibrillation, as well as those with implanted mechanical heart valves and left ventricular assist devices. Tecarfarin holds orphan drug designations for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as for those with left ventricular assist devices (LVADs).Pham also referenced Fruinexian, a short-acting Factor XI candidate acquired in late 2025 for use in cardiovascular surgery, noting broader industry interest in Factor XI inhibitors as the company awaits the first approvals in the class.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Cadrenal was ‘neutral’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cvkd_ss_png_379707bd48.webp" alt="cvkd ss.png" width="969" height="140"><figcaption>CVKD sentiment and message volume as of January 19 | Source: Stocktwits</figcaption></figure>One user said, “<a href="https://stocktwits.com/symbol/CVKD">$CVKD</a> is showing early strength.”<stembedurl>https://stocktwits.com/JoannMotta/message/642239634</stembedurl>&nbsp;Another user described the stock’s current levels as a zone to keep&nbsp;an eye on.<stembedurl>https://stocktwits.com/LydiaBoyce/message/642238255</stembedurl><a href="https://stocktwits.com/symbol/CVKD">Cadrenal’s stock</a> has declined 57% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Equity

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics, Inc. (CVKD) on Monday announced the acquisition of new assets from eXIthera Pharmaceuticals.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/15/3149938/0/en/Cadrenal-Therapeutics-Enhances-Anticoagulation-Pipeline-Through-Acquisition-of-eXIthera-s-Portfolio-of-Factor-XIa-Inhibitors.html">said</a> that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings. As per the deal, eXIthera will receive milestone payments from Cadrenal totaling up to $15 million, subject to the realization of certain future clinical and regulatory milestones. eXIthera will also be entitled to royalties on global sales of the acquired assets upon future commercialization.CVKD shares jumped 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The deal includes eXIthera’s portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, a new class of anticoagulants. This includes eXIthera’s lead asset, Frunexian, being studied for acute anticoagulation, EP-7327, an oral small molecule candidate for chronic indications, and an extensive portfolio of additional small molecules.“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Cadrenal CEO Quang X. Pham.“With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk,” he added.Sichuan Haisco Pharmaceuticals retains rights to Frunexian in China under a pre-existing license agreement, the company said. Cadrenal will, however, be entitled to receive royalties of Frunexian sales in China.CVKD stock is down 8% this year but up approximately 20% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-rate-cut-this-week-too-late-powell-bigger-than-he-had-in-mind/chwwONNRdUh">Trump Says ‘Too Late’ Powell Must Cut Rates Now, And ‘Bigger Than He Had In Mind’ Ahead Of Fed Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

CVKD
Cadrenal Therapeutics, Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CVKD News

CVKDCadrenal Therapeutics, Inc.